EUVIMEDEUVIMED entdecken
Crossref

Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease

Shivani Sharma, Saroj Kumar, Manendra Singh Tomar, Divya Chauhan, Chirag Kulkarni, Swati Rajput, Sreyanko Sadhukhan, Konica Porwal, Rajdeep Guha, Ashutosh Shrivastava, Jiaur R Gayen, Navin Kumar und 1 weitere

Bone · 2024

DOI: 10.1016/j.bone.2024.117126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bone, 2024. Verfasst von Shivani Sharma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Centre for Research in ASTHI, CSIR-Central Drug Research Institute, Council of Scientific and Industrial Research, Luck…. Hauptthemen laut MEDLINE: Hyperparathyroidism, Secondary, Renal Insufficiency, Chronic, Bone and Bones, Peptides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Science and Engineering Research Board, Central Drug Research Institute, Council of Scientific and Industrial Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease-induced secondary hyperparathyroidism (CKD-SHPT) heightens fracture risk through impaired mineral homeostasis and elevated levels of uremic toxins (UTs), which in turn enhance bone remodeling. Etelcalcetide (Etel), a calcium-sensing receptor (CaSR) agonist, suppresses parathyroid hormone (PTH) in hyperparathyroidism to reduce excessive bone resorption, leading to increased bone mass. However, Etel's effect on bone quality, chemical composition, and strength is not well understood. To address these gaps, we established a CKD-SHPT rat model and administered Etel at a human-equivalent dose concurrently with disease induction. The effects on bone and mineral homeostasis were compared with a CKD-SHPT (vehicle-treated group) and a control group (rats without SHPT). Compared with vehicle-treated CKD-SHPT rats, Etel treatment improved renal function, reduced circulating UT levels, improved mineral homeostasis parameters, decreased PTH levels, and prevented mineralization defects. The upregulation of mineralization-promoting genes by Etel in CKD-SHPT rats might explain its ability to prevent mineralization defects. Etel preserved both trabecular and cortical bones with attendant suppression of osteoclast function, besides increasing mineralization. Etel maintained the number of viable osteocytes to the control level, which could also contribute to its beneficial effects on bone. CKD-SHPT rats displayed increased carbonate substitution of matrix and mineral, decreased crystallinity, mineral-to-matrix ratio, and collagen maturity, and these changes were mitigated by Etel. Further, Etel treatment prevented CKD-SHPT-induced deterioration in bone strength and mechanical behavior. Based on these findings, we conclude that in CKD-SHPT rats, Etel has multiscale beneficial effects on bone that involve remodeling suppression, mineralization gene upregulation, and preservation of osteocytes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperparathyroidism, SecondaryRenal Insufficiency, ChronicBone and BonesPeptidesCalcimimetic AgentsRats, Sprague-DawleyAnimalsRatsParathyroid HormoneMaleCalcification, PhysiologicBone Density

Stichwörter der Autor:innen

Bone-qualityEtelcalcetideHistomorphometryMechanical strengthSecondary hyperparathyroidismmicro-computed tomography

Substanzen

etelcalcetide hydrochloridePeptidesCalcimimetic AgentsParathyroid Hormone

Autor:innen und Institutionen

  • Division of Endocrinology and Centre for Research in ASTHI, CSIR-Central Drug Research Institute, Council of Scientific and Industrial Research, Lucknow 226031, India; Academy of Scientific and Innovative Research (AcSI…
  • Department of Mechanical Engineering, Indian Institute of Technology Ropar, Rupnagar, Punjab 140001, India.
  • Center for Advance Research, Faculty of Medicine, King George's Medical University, Lucknow 226003, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Council of Scientific and Industrial Research, Luckno…
  • Division of Endocrinology and Centre for Research in ASTHI, CSIR-Central Drug Research Institute, Council of Scientific and Industrial Research, Lucknow 226031, India.
  • Division of Laboratory Animal Facility, CSIR-Central Drug Research Institute, Council of Scientific and Industrial Research, Lucknow 226031, India.

Förderung

  • Science and Engineering Research Board
  • Central Drug Research Institute
  • Council of Scientific and Industrial Research

Zitieren

APA

Sharma, S., Kumar, S., Tomar, M. S., Chauhan, D., Kulkarni, C., Rajput, S., Sadhukhan, S., Porwal, K., Guha, R., Shrivastava, A., Gayen, J. R., Kumar, N., & Chattopadhyay, N. (2024). Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease. Bone. https://doi.org/10.1016/j.bone.2024.117126

Vancouver

Sharma S, Kumar S, Tomar MS, Chauhan D, Kulkarni C, Rajput S, et al. Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease. Bone. 2024. doi:10.1016/j.bone.2024.117126

BibTeX
@article{Sharma2024,
  author = {Sharma, Shivani and Kumar, Saroj and Tomar, Manendra Singh and Chauhan, Divya and Kulkarni, Chirag and Rajput, Swati and Sadhukhan, Sreyanko and Porwal, Konica and Guha, Rajdeep and Shrivastava, Ashutosh and Gayen, Jiaur R and Kumar, Navin and Chattopadhyay, Naibedya},
  title = {Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease},
  journal = {Bone},
  year = {2024},
  doi = {10.1016/j.bone.2024.117126}
}
Kostenlos starten →